IMCLISFA Trademark

Trademark Overview


On Monday, November 6, 2023, a trademark application was filed for IMCLISFA with the United States Patent and Trademark Office. The USPTO has given the IMCLISFA trademark a serial number of 98257351. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Sunday, December 1, 2024. This trademark is owned by Ideaya Biosciences, Inc.. The IMCLISFA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations, namely, an orally administered protein kinase C (PKC) inhibitor for treating cancer, tumors, melanoma, and carcinoma; pharmaceutical and biological preparations for use in oncology for medical treatment purposes; pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, tumors, melanoma, and carcinoma; pharmaceutical and biological preparations for preventing, diagnosing, treating and managing metastatic uveal melanoma, primary uveal melanoma, and cutaneous melanoma; therapeutic agents for targeting genetically defined cancers or tumors having GNAQ or GNA11 gene mutations, and destruction of diseased cells, for medical treatment purposes
imclisfa

General Information


Serial Number98257351
Word MarkIMCLISFA
Filing DateMonday, November 6, 2023
Status645 - FINAL REFUSAL - MAILED
Status DateSunday, December 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations, namely, an orally administered protein kinase C (PKC) inhibitor for treating cancer, tumors, melanoma, and carcinoma; pharmaceutical and biological preparations for use in oncology for medical treatment purposes; pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, tumors, melanoma, and carcinoma; pharmaceutical and biological preparations for preventing, diagnosing, treating and managing metastatic uveal melanoma, primary uveal melanoma, and cutaneous melanoma; therapeutic agents for targeting genetically defined cancers or tumors having GNAQ or GNA11 gene mutations, and destruction of diseased cells, for medical treatment purposes
Translation of Words in MarkThe wording IMCLISFA has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 4, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIdeaya Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Thursday, November 9, 2023NEW APPLICATION ENTERED
Monday, December 4, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 14, 2024ASSIGNED TO EXAMINER
Wednesday, June 19, 2024NON-FINAL ACTION E-MAILED
Wednesday, November 6, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 19, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 19, 2024NON-FINAL ACTION WRITTEN
Thursday, September 19, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, September 19, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, November 6, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 6, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, December 1, 2024FINAL REFUSAL E-MAILED
Sunday, December 1, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Sunday, February 16, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, February 16, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, February 16, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sunday, December 1, 2024FINAL REFUSAL WRITTEN